163 related articles for article (PubMed ID: 22278729)
1. In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds.
Teichmann K; Kuliberda M; Schatzmayr G; Hadacek F; Joachim A
Parasitol Res; 2012 Jul; 111(1):231-40. PubMed ID: 22278729
[TBL] [Abstract][Full Text] [Related]
2. Effect of Ginsenoside-Rh2 and Curcurbitacin-B on Cryptosporidium parvum in vitro.
Shahiduzzaman M; Ras R; Widmer G
Exp Parasitol; 2020 May; 212():107873. PubMed ID: 32165146
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibitory effects of plant-derived by-products against Cryptosporidium parvum.
Teichmann K; Kuliberda M; Schatzmayr G; Pacher T; Zitterl-Eglseer K; Joachim A; Hadacek F
Parasite; 2016; 23():41. PubMed ID: 27627637
[TBL] [Abstract][Full Text] [Related]
4. Anti-protozoal activity of extracts from chicory (Cichorium intybus) against Cryptosporidium parvum in cell culture.
Woolsey ID; Valente AH; Williams AR; Thamsborg SM; Simonsen HT; Enemark HL
Sci Rep; 2019 Dec; 9(1):20414. PubMed ID: 31892721
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
6. Effects of curcumin on Cryptosporidium parvum in vitro.
Shahiduzzaman M; Dyachenko V; Khalafalla RE; Desouky AY; Daugschies A
Parasitol Res; 2009 Oct; 105(4):1155-61. PubMed ID: 19557435
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory activity of chitosan nanoparticles against Cryptosporidium parvum oocysts.
Ahmed SA; El-Mahallawy HS; Karanis P
Parasitol Res; 2019 Jul; 118(7):2053-2063. PubMed ID: 31187224
[TBL] [Abstract][Full Text] [Related]
8. The Existing Drug Vorinostat as a New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases.
Guo F; Zhang H; McNair NN; Mead JR; Zhu G
J Infect Dis; 2018 Mar; 217(7):1110-1117. PubMed ID: 29300993
[TBL] [Abstract][Full Text] [Related]
9. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
Morales Gomez MA
Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum.
Klein P; Cirioni O; Giacometti A; Scalise G
J Antimicrob Chemother; 2008 Nov; 62(5):1101-4. PubMed ID: 18653486
[TBL] [Abstract][Full Text] [Related]
11. Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells.
Gargala G; Delaunay A; Favennec L; Brasseur P; Ballet JJ
Int J Parasitol; 1999 May; 29(5):703-9. PubMed ID: 10404264
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
[TBL] [Abstract][Full Text] [Related]
13. Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method.
Armson A; Meloni BP; Reynoldson JA; Thompson RC
FEMS Microbiol Lett; 1999 Sep; 178(2):227-33. PubMed ID: 10499272
[TBL] [Abstract][Full Text] [Related]
14. Novel and promising compounds to treat Cryptosporidium parvum infections.
Graczyk Z; Chomicz L; Kozłowska M; Kazimierczuk Z; Graczyk TK
Parasitol Res; 2011 Sep; 109(3):591-4. PubMed ID: 21344209
[TBL] [Abstract][Full Text] [Related]
15. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
Nelson RG; Rosowsky A
Antimicrob Agents Chemother; 2001 Dec; 45(12):3293-303. PubMed ID: 11709300
[TBL] [Abstract][Full Text] [Related]
16. Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.
Li K; Nader SM; Zhang X; Ray BC; Kim CY; Das A; Witola WH
PLoS Pathog; 2019 Jul; 15(7):e1007953. PubMed ID: 31356619
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a cell culture based assay for in vitro assessment of anticryptosporidial compounds.
Najdrowski M; Heckeroth AR; Wackwitz C; Gawlowska S; Mackenstedt U; Kliemt D; Daugschies A
Parasitol Res; 2007 Jun; 101(1):161-7. PubMed ID: 17216237
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
Kuhlenschmidt TB; Rutaganira FU; Long S; Tang K; Shokat KM; Kuhlenschmidt MS; Sibley LD
Antimicrob Agents Chemother; 2016 Jan; 60(1):570-9. PubMed ID: 26552986
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of putative anti-cryptosporidial drugs in an in vitro culture system.
Schupfner M; Greif G; Lendner M; Daugschies A; Lippuner C; von Samson-Himmelstjerna G; Krücken J
Parasitol Res; 2013 Aug; 112 Suppl 1():149-62. PubMed ID: 23765343
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
Downey AS; Chong CR; Graczyk TK; Sullivan DJ
Antimicrob Agents Chemother; 2008 Sep; 52(9):3106-12. PubMed ID: 18591280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
